Terns Pharmaceuticals, INC 10-Q quarterly reports

Terns Pharmaceuticals reports strong TERN-701 data and FDA Orphan Drug Designation, while discontinuing its metabolic disease programs to streamline its pipeline.

Terns Pharmaceuticals reports positive clinical data for its lead oncology and obesity programs, extending its cash runway into 2028 while strategically seeking partnerships for metabolic assets.

Terns Pharmaceuticals reports a net loss for Q1 2025, alongside updates on its clinical programs and executive transitions.

Terns Pharmaceuticals reported its financial results for the third quarter of 2024, highlighting progress in its clinical programs and a recent capital raise.

Terns Pharmaceuticals reported a net loss of $22.7 million for the second quarter of 2024, while highlighting progress in its clinical programs and strategic focus on oncology and obesity.

Terns Pharmaceuticals reported a net loss of $22.4 million for the first quarter of 2024, while highlighting progress in its clinical programs and a leadership transition.